Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adal
Go back to Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adal| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 118.05 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $118.05 | 52 Week High | $118.49 | |||
| Open | $118.05 | 52 Week Low | $55.00 | |||
| Day High | $118.05 | P/E | N/A | |||
| Day Low | $118.05 | EPS | $-0.56 | |||
| Volume | 350 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1235.56 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1235.56 | 52 Week High | $88.16 | |||
| Open | $1235.56 | 52 Week Low | $67.88 | |||
| Day High | $1235.56 | P/E | 286.01 | |||
| Day Low | $1235.56 | EPS | $4.32 | |||
| Volume | 16,675 | |||||
